Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.
Also called NCT05970679
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 252 participants
- Registry
-
NCT05970679
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05970679. Randomized; quadruple masking; primary purpose treatment. Start 2022-08-17 (actual); primary completion 2023-04-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
- Condition
- Hypercholesterolemia, Dyslipidemia
- Intervention (Drug)
- Ezetimibe/Atorvastatin 10/5 mg
- Intervention (Drug)
- Atorvastatin 5mg
- Intervention (Drug)
- Ezetimibe 10mg
- Intervention (Drug)
- Atorvastatin 10mg
- Intervention (Drug)
- DW1125 placebo
- Intervention (Drug)
- DW1125A placebo
- Intervention (Drug)
- DW1125E placebo
- Intervention (Drug)
- DW1125A-1 placebo
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05970679- Content hash
fbd0f2245252c69d05e5af40c3535eb7ae511c8629924ae03aef5de028bbf654